GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding GRI Bio, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 9 | 5 | −4 |
| Shares | 104.4K | 1.20M | +1.09M (+1,047.3%) |
| Value | $37.4K | $5.09M | +$5.05M (+13,496.5%) |
New holders (1)
Institutions that held GRI Bio, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Altium Capital Management LP | 1,179,286 | $5.01M | 3.92% |
Sold out (5)
Institutions that held GRI Bio, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Two Sigma Securities, LLC | 22,708 | $8.21K |
| State Street Corp | 18,921 | $6.84K |
| Susquehanna International Group, LLP | 15,109 | $5.46K |
| Citadel Advisors LLC | 11,095 | $4.01K |
| Archer Investment Corp | 100 | $36 |